Priority Review for Bristol Myers Lung Cancer Treatment

 Application based on results from the registrational TRIDENT-1 trial, in which repotrectinib demonstrated high response rates and durable responses in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer

If approved, repotrectinib will provide a potential best-in-class option for patients with ROS1-positive NSCLC who are TKI-naïve and a potential first-in-class treatment for patients who have been treated with prior TKI

The U.S. Food and Drug Administration assigned a target action date of November 27, 2023

https://www.biospace.com/article/releases/u-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibb-s-application-for-repotrectinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer/